EU regulatory framework for biologics and biosimilarity MCQs With Answer

Introduction

EU regulatory framework for biologics and biosimilarity is crucial for M.Pharm students preparing for careers in regulatory affairs, quality, clinical development, or pharmacovigilance. This short quiz collection focuses on the European Medicines Agency (EMA) requirements, key EU regulations and directives, and scientific principles used to evaluate biosimilars — including comparability, quality attributes, clinical and immunogenicity assessment, extrapolation of indications, and post‑marketing obligations. Questions emphasize practical regulatory pathways (centralised procedure, CHMP, CAT), relevant guidelines (e.g., ICH Q5E), and national versus EU roles such as interchangeability and substitution. The set is designed to deepen conceptual understanding and prepare students for real‑world regulatory decision making.

Q1. What is the primary EU regulatory route for approval of biosimilar medicinal products?

• Decentralised procedure handled by national authorities
• Mutual recognition procedure initiated in one member state
• Centralised procedure through the European Medicines Agency (EMA)
• National authorisation in each EU country separately

Correct Answer: Centralised procedure through the European Medicines Agency (EMA)

Q2. Which EMA committee is mainly responsible for scientific assessment of biosimilar applications?

• Committee for Advanced Therapies (CAT)
• Committee for Medicinal Products for Human Use (CHMP)
• Pharmacovigilance Risk Assessment Committee (PRAC)
• Paediatric Committee (PDCO)

Correct Answer: Committee for Medicinal Products for Human Use (CHMP)

Q3. Which EU legal act lays down general rules for medicinal products for human use and is central to biologics regulation?

• Directive 2001/83/EC
• Regulation (EU) 2017/745
• Regulation (EC) No 726/2004
• Directive 2003/94/EC

Correct Answer: Directive 2001/83/EC

Q4. According to EU guidance, what is the cornerstone concept for demonstrating biosimilarity?

• Demonstration of identical primary sequence only
• Stepwise comparability encompassing analytical, non‑clinical and clinical data
• Single pivotal clinical trial with the proposed biosimilar versus placebo
• Reliance solely on literature data for the reference product

Correct Answer: Stepwise comparability encompassing analytical, non‑clinical and clinical data

Q5. Which ICH guideline specifically addresses comparability of biotechnology‑derived products after changes in manufacturing?

• ICH Q8 (Pharmaceutical Development)
• ICH Q5E (Comparability of Biotechnological/Biological Products)
• ICH Q9 (Quality Risk Management)
• ICH M4 (CTD)

Correct Answer: ICH Q5E (Comparability of Biotechnological/Biological Products)

Q6. For a biosimilar application in the EU, what reference product should generally be used in comparative studies?

• Any licensed product from outside the EU
• The innovator product authorised in the EU (EU‑RMP)
• A locally produced copy from a national market
• An international non‑proprietary reference from WHO

Correct Answer: The innovator product authorised in the EU (EU‑RMP)

Q7. Under EU practice, which of the following is TRUE about extrapolation of indications for a biosimilar?

• Extrapolation is automatic for all indications once one indication is approved
• Extrapolation is allowed only if scientific justification addresses mechanism of action and similarity across indications
• Extrapolation is forbidden under EU rules
• Extrapolation requires separate full clinical trials for each indication

Correct Answer: Extrapolation is allowed only if scientific justification addresses mechanism of action and similarity across indications

Q8. Which EU body evaluates advanced therapy medicinal products (ATMPs) and provides specialised assessment distinct from typical biosimilars?

• PRAC (Pharmacovigilance Risk Assessment Committee)
• CAT (Committee for Advanced Therapies)
• EPAR (European Public Assessment Report)
• EDQM (European Directorate for the Quality of Medicines)

Correct Answer: CAT (Committee for Advanced Therapies)

Q9. In the EU, who is primarily responsible for final decisions on interchangeability and automatic substitution of biosimilars?

• European Medicines Agency (EMA)
• European Commission (EC)
• Each individual member state / national competent authorities
• World Health Organization (WHO)

Correct Answer: Each individual member state / national competent authorities

Q10. Which regulatory document requires manufacturers to have an RMP (Risk Management Plan) for biologics approved in the EU?

• Guideline on Good Laboratory Practice (GLP)
• Regulation (EC) No 726/2004 and related EMA guidance
• Directive on Waste Management
• ICH Q7 (Good Manufacturing Practice for APIs)

Correct Answer: Regulation (EC) No 726/2004 and related EMA guidance

Q11. Which of the following analytical attributes is most critical when establishing biosimilarity for monoclonal antibodies?

• Color of the final solution
• Glycosylation profile and Fc receptor binding
• Type of glass vial used
• Geographic origin of the cell bank only

Correct Answer: Glycosylation profile and Fc receptor binding

Q12. What is the role of immunogenicity testing in EU biosimilar development?

• It is optional and rarely required
• It is a key part of clinical comparability to assess anti‑drug antibodies and safety
• It can be replaced entirely by in vitro assays
• It is only required for oral biologics

Correct Answer: It is a key part of clinical comparability to assess anti‑drug antibodies and safety

Q13. Which pharmacovigilance system is used across the EU for reporting adverse reactions for biosimilars?

• EudraVigilance
• FDA Adverse Event Reporting System (FAERS)
• VigiBase only
• Manufacturer internal database only

Correct Answer: EudraVigilance

Q14. Which concept explains why very sensitive analytical comparison may reduce the need for extensive clinical efficacy trials for a biosimilar?

• Extrapolation principle
• Comparability concept or totality of evidence
• Clinical non‑inferiority assumption
• Market exclusivity doctrine

Correct Answer: Comparability concept or totality of evidence

Q15. Which of the following is NOT typically required in a biosimilar marketing authorisation dossier in the EU?

• Extensive head‑to‑head analytical and functional characterisation
• Comparative clinical immunogenicity and PK/PD studies
• Full copy of the innovator’s proprietary manufacturing process details
• Risk Management Plan and pharmacovigilance measures

Correct Answer: Full copy of the innovator’s proprietary manufacturing process details

Q16. What is the significance of the “comparability exercise” invoked in EU biologics regulation?

• It allows changing the indication without any studies
• It assesses whether observed differences affect safety or efficacy after manufacturing or between products
• It is only relevant for small‑molecule generics
• It replaces the need for any analytical testing

Correct Answer: It assesses whether observed differences affect safety or efficacy after manufacturing or between products

Q17. Which guidance addresses biosimilars containing monoclonal antibodies specifically in the EU?

• EMA guideline on similar biological medicinal products containing monoclonal antibodies
• ICH Q3 (Impurities)
• Guideline on Herbal Medicinal Products
• European Pharmacopoeia Chapter on Water for Injection

Correct Answer: EMA guideline on similar biological medicinal products containing monoclonal antibodies

Q18. If a manufacturer makes a post‑approval change to a biologic’s manufacturing site, what EU requirement is most relevant?

• No notification is needed once the product is authorised
• Performing a comparability exercise and notifying/approving the change per variations guidance
• Immediate withdrawal of the product from market
• Only updating the package leaflet is sufficient

Correct Answer: Performing a comparability exercise and notifying/approving the change per variations guidance

Q19. Which document publicly summarises EMA’s scientific assessment and approval rationale for an authorised biosimilar?

• European Public Assessment Report (EPAR)
• Marketing Authorisation Holder (MAH) confidential file
• National Prescription Database
• Pharmacopoeial monograph only

Correct Answer: European Public Assessment Report (EPAR)

Q20. Which requirement ensures manufacturing quality for EU biologics and biosimilars?

• Good Distribution Practice (GDP) only
• Good Manufacturing Practice (GMP) and EMA inspections of production facilities
• No inspection is required for biologics
• Only labelling requirements matter for quality

Correct Answer: Good Manufacturing Practice (GMP) and EMA inspections of production facilities

Download